Karyopharm Therapeutics Inc. (KPTI)

Market Cap	37.67M
Revenue (ttm)	142.13M
Net Income (ttm)	-62.52M
Shares Out	8.64M
EPS (ttm)	-12.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,694
Open	4.340
Previous Close	4.310
Day's Range	4.250 - 4.480
52-Week Range	3.510 - 16.950
Beta	0.23
Analysts	Buy
Price Target	48.50 (+1,012.39%)
Earnings Date	Aug 5, 2025

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 279
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI
• Website: https://www.karyopharm.com

Financial Performance

In 2024, Karyopharm Therapeutics's revenue was $145.24 million, a decrease of -0.55% compared to the previous year's $146.03 million. Losses were -$76.42 million, -46.60% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price target is $48.5, which is an increase of 1,012.39% from the latest price.

Price Target

$48.5

(1,012.39% upside)

Analyst Consensus: Buy